Publisher
Springer Science and Business Media LLC
Subject
Emergency Medicine,Internal Medicine
Reference24 articles.
1. https://www.ema.europa.eu/en/news/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic#:~:text=EMA’s%20safety%20committee%20(PRAC)%20has,clots%2C%20cancer%20and%20serious%20infections. Accessed 10 Aug 2023
2. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316–326
3. Salinas CA, Louder A, Polinski J, Zhang TC, Bower H, Phillips S et al (2022) Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases. Rheumatol Ther Internet. https://doi.org/10.1007/s40744-022-00505-1
4. Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J, ARTIS study group (2022) Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis. https://doi.org/10.1136/ard-2022-223050. (Epub ahead of print. PMID: 36150749)
5. Setyawan J, Mu F, Yarur A, Zichlin ML, Yang H, Fernan C et al (2021) Risk of thromboembolic events and associated risk factors, including treatments, patients with immune-mediated. Diseases Clin Ther 43(8):1392-1407.e1
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献